Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis

Next Previous
Search
Trial Profile

A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daprodustat (Primary) ; Darbepoetin alfa; Epoetin alfa; Ferrous sulfate; Iron; Recombinant erythropoietin
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 20 Oct 2022 Status changed from active, no longer recruiting to completed.
    • 22 Jul 2022 Planned End Date changed from 29 Jul 2022 to 23 Sep 2022.
    • 22 Jul 2022 Planned primary completion date changed from 29 Jul 2022 to 23 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top